Coronary heart disease (CHD) is a prevalent and chronic life-threatening disease. However, there is no reliable way for early diagnosis and prevention of CHD so far. The precise molecular pathological mechanism of CHD remains obscure. Therefore, developing novel biomarkers is urgently needed.
C oronary heart disease (CHD) is the leading cause of morbidity and mortality worldwide. 1, 2) It is characterized by endothelial dysfunction and chronic inflammation, which interact with metabolic changes to trigger and propagate the development of lesions in the vessel walls. 3, 4) Despite the establishment of several risk factors for CHD, such as hyperlipidemia, diabetes mellitus, and obesity, the molecular mechanisms underlying its pathogenesis and progression are still not completely understood. [5] [6] [7] This has impeded the early diagnosis, treatment, and prevention of CHD. Therefore, it is necessary to explore novel analytical methods to identify novel biomarkers that would increase our understanding of the mechanisms of this disease and may lead to improved clinical decision-making.
Metabolomics is defined as the "quantitative measurement of the dynamic multiparametric metabolic responses of living systems to pathophysiological stimuli or genetic modifications." 8) Untargeted metabolomic technologies capture numerous small molecules in a biosample (tissue, serum, plasma, or urine), representing multiple pathways and functional classes. This offers a novel approach for the investigation of disease mechanisms and identification of biomarkers. In recent decades, an increasing number of metabolomics studies have been utilized in the study of atherosclerosis, [9] [10] [11] [12] myocardial ischemia, [13] [14] [15] heart failure, 16) and hypertension. 17) Recently, nontargeted metabolomics has successfully characterized metabolic changes associated with CHD and helped identify new biomarkers. [18] [19] [20] [21] [22] More recent metabolomic analyses of patients with CHD have used liquid chromatography-mass spectrometry (LC-MS) to identify significant metabolic changes in patients with CHD compared with healthy controls. 21, 22) For instance, Feng, et al. 21) identified GlcNAc-6-P, mannitol, and 15 plasma cholines as potential biomarkers for CHD, whereas Li, et al. 22) re-FU, ET AL vealed that seven metabolites were significantly disrupted in a group of patients with CHD. However, both studies used healthy individuals as controls. To date, few studies have focused on the abnormalities of metabolic pathways or biomarkers between patients with CHD and angiographically normal controls.
In this study, we applied LC quadrupole time-offlight MS (LC/Q-TOF/MS) metabolomics to plasma samples obtained from patients with CHD and controls diagnosed and confirmed by coronary angiography. Our aim was to determine whether metabolomics based on LC/Q-TOF/MS could discriminate patients with CHD from controls. Subsequently, we identified potential biomarkers for CHD and explored their related metabolic pathways. Finally, a second study was performed on an independent population (40 patients with CHD and 40 controls) to validate the discrimination performance of the biomarkers and confirm their potential as diagnostic indicators.
Methods

Clinical participants and sample collection:
This study was approved by the Ethics Review Committee of the First Hospital of Harbin City. Patients who underwent coronary angiography for the diagnosis of coronary artery disease owing to symptoms of chest pain, cardiovascular risk factors, or ischemic changes in electrocardiography at the Department of Cardiology of the First Hospital of Harbin City (Harbin, China) between November 1, 2015, and July 30, 2016, were enrolled in this study. We defined patients with CHD as individuals with newly diagnosed, angiographically documented coronary stenosis of > 75% in at least one major coronary artery. 22) Subjects with angiographically documented normal coronary artery or coronary stenosis of < 50% were defined as the controls. Patients were excluded if they had a myocardial infarction or previous myocardial infarction; coronary revascularization or percutaneous coronary intervention; heart failure; or any metabolic disease, liver/renal disease, or inflammatory disease while participating in the current study. All participants provided their written informed consent.
The participants provided details of age, sex, cardiac risk factors, and prior cardiac disease and underwent hematological and biochemical examinations. Peripheral venous blood samples (5 mL) were collected in the morning before breakfast from patients with CHD and controls using Vacutainer tubes containing a fresh sodium dihydrogen phosphate (EDTA-K3) anticoagulant. The blood samples were centrifuged at 1000 ×g for 10minutes to separate the supernatant (plasma), which was then frozen and stored at −80°C until required for further analysis. Blank and quality control samples: In order to assess the stability of the analytical instrument and sample carryover, blank and quality control (QC) samples were analyzed throughout the entire experimental procedure. One blank sample (75% acetonitrile) was run for every six samples to identify and minimize the sample carryover. QC samples were prepared by mixing equal aliquots of plasma from each real sample. One QC sample was inserted regularly after running every 12 real samples. Sample preparation: Prior to LC/Q-TOF/MS analysis, all plasma and QC samples were thawed and refrozen using a 4°C water bath. Aliquots of 100 μL were injected into vials, and 500 μL of methanol was added and vortex-mixed vigorously for 2 minutes. The mixture was then centrifuged at 14,000 ×g for 15 minutes at 4°C, and the supernatant was transferred to a clear vial to nitrogen-dry at 37°C. The residue was dissolved in 100 μL of acetonitrile/ water (3 : 1), which was kept at 30°C for 10minutes and then vortexed for 60seconds. The supernatant was then placed into a sampling vial, pending LC/Q-TOF/MS analysis. 23) Chromatography: A 10 μL aliquot of the pretreatment sample was injected into a 2.1 × 100 mm (1.8 μm) ZOR-BAX SB-C18 column (Agilent, Wilmington, NC, USA) held at 40°C using the LC system (1260 Series; Agilent). Plasma samples from patients with CHD and controls were alternatively run. The binary gradient elution system consisted of A = water with 0.1% formic acid and B = acetonitrile with 0.1% formic acid for the positive ion mode, with A = water and B = acetonitrile for the negative ion mode. Separation was achieved using the following linear gradient: 5% B, held for 1minute; 1-18minutes, increased to 95% B; and 18-21minutes, held at 95% B. After the analytical run, the gradient was returned to 5% B in 0.1minutes and equilibrated at 5% B for 7minutes. The flow rate was 0.4 mL/minute. All samples were maintained at 4°C during the analysis. 24) Mass spectrometry: MS data were collected using an Agilent 6530 Series Q-TOF MS equipped with a dual electrospray ionization (ESI) source. The ionization was operated in positive (ESI+) or negative (ESI−) mode. The source temperature was set at 350°C with a desolvation gas flow of 10 L/hour. The capillary voltage was 4.0 kV for the positive mode and 3.5 kV for the negative mode. Data were collected in the centroid mode from 50 to 1,000 m/z with a full scan rate of two scans per second. In order to ensure mass accuracy and reproducibility, the MS was internally mass-calibrated in real time with purine (m/z 121.0509 and m/z 119.0363 in the ESI+ mode and ESI− mode, respectively). The targeted MS/MS mode was used to identify potential biomarkers with high-purity nitrogen as the collision gas. The collision energy was set at 10, 20, or 40 eV. 23) Data preprocessing and annotation: The acquired MS data were converted into mzData format by MassHunter Qualitative Analysis Software (Agilent) and then imported to the xcms package in R platform for preprocessing. 24) All parameters used default values. 25) The preprocessing result generated a three-dimensional dataset including the retention time, mass-to-charge ratio (m/z), and peak intensities. Then, the R package CAMERA was used to annotate isotope peaks, adducts, and fragments in the peak lists. 26) Normalization to total peak intensities for each sample was performed before the statistical analysis. 27) Statistical analysis: Normalized data were imported into SIMCA-P 11.5 software (Umetrics AB, Umeå, Sweden) for multivariate data analysis. Principal component analysis (PCA) was first used to provide a comprehensive view of the clustering trends and outliers in an unsupervised manner. 28) Partial least-squares discriminant analysis (PLS-DA) was then employed to visualize the global metabolic changes between patients with CHD and controls and to identify potential disease biomarkers. The variable importance in projection (VIP) values of all peaks from the PLS-DA model was taken as a coefficient for potential marker selection. 29) Those variables with VIP > 1 were considered relevant for group discrimination. The nonparametric Kruskal-Wallis test was also used to measure the significance of each metabolite. Metabolites with both multivariate and univariate statistical significance (VIP > 1.0 and P < 0.05) were considered to be potential metabolic biomarkers capable of differentiating patients with CHD from controls. In order to validate the robustness of the supervised PLS-DA model and to evaluate the degree of overfitting, permutation tests with 100 iterations were performed. 30) The dataset was divided into a training set and a test set. The training set was used to generate the classification model, and the independent test set was then subjected to the constructed model to evaluate its diagnostic ability. In order to build the classification model, a binary logistic regression analysis was performed using SPSS software (IBM SPSS Statistics 22; IBM Corp., Armonk, NY, USA). In the training set study, a receiver operating characteristic (ROC) curve analysis was carried out to calculate the optimal cut-off value and area under the curve (AUC), sensitivity, and specificity. In the validation set study, the classification model was reevaluated using different samples, and the specificity, sensitivity, and AUC of the model were examined using the cut-off value obtained from the training set. Identification of potential biomarkers: First, corresponding quasi-molecular ions were identified by analyzing the peak list and annotation results. Second, MS/MS experiments were performed on a Q-TOF/MS system (6530 Agilent) to produce the fragment patterns and structural information for the selected biomarkers. Third, the identification of each biomarker was based on mass data, retention time, MS/MS product ion patterns, and an online database query. 25) The fragmentation patterns of the biomarkers were compared with the spectral data of the metabolites that had the same m/z in freely available databases (HMDB 31) [www.hmdb.ca] and METLIN 31) [http:// metlin.scripps.edu/]). The mass tolerance between the measured m/z value and the exact mass of the component of interest was set to within 10 ppm. Finally, if available, confirmation with standards was performed by comparing retention times, isotopic distributions, and fragments of commercially available reagents (Sigma-Aldrich, St. Louis, MO, USA) with those obtained in real examples.
Results
Characteristics of participants:
This study included 107 patients with CHD confirmed by coronary angiography and 92 controls. The enrolled subjects were separated into a training set (67 patients and 52 controls), for biomarker identification and establishment of a model for discrimination of patients with CHD and controls, and a test set (40 patients and 40 controls), for validation of that model. The baseline characteristics and clinical parameters of these participants are summarized in Table I . Except for apolipoprotein A (apoA), apolipoprotein B (apoB), cre-atine kinase-muscle/brain (CK-MB), troponin I in the training set, high-density lipoprotein (HDL), and apoA in the test set, there were no significant differences in the age, gender, cardiac risk factors, or other clinical characteristics between the two groups.
By design, all patients with CHD had significant angiographically documented stenosis in at least one major coronary artery, with a mean percentage of 90.19 ± 10.41% in the training set and 81.18 ± 12.59% in the test set. None of the controls had any significant lesions in their coronary arteries.
Plasma metabolic profiling based on LC/Q-TOF/MS:
In order to survey metabolite changes at an overview level, we acquired metabolic profiling of 119 plasma samples based on LC/Q-TOF/MS in both positive and negative ion modes. A total of 1,814 aligned individual peaks (variables) in the positive mode and 1,683 in the negative mode were obtained. These peaks included quasimolecular ions, isotope ions, adduct ions, and fragment ions of the metabolites. Representative LC/Q-TOF/MS chromatograms from patient and control groups are shown in Figure 1 .
Unbiased PCA was initially performed on the entire dataset to check the grouping trend and outliers. Although no clear separation was observed between patients and controls in the PCA score plot, there were no extreme outliers that needed to be excluded from subsequent analyses ( Figure 2 ). The score plots from the PCA model also revealed tight clustering of QC samples, indicating good instrumental reproducibility throughout the analytical period.
After the initial overview, the data were subjected to PLS-DA to further explore the metabolic differences between patients with CHD and controls. As shown in Figure 3A and C, patients with CHD and controls were distributed in two separate areas in both positive and negative modes, indicating a marked metabolic difference between the two groups at an overview level. The quality of the models was assessed by the parameters R 2 X, R 2 Y, and Q 2 , where R 2 provides the model validity in the form of an explained variance result and indicated the goodness of fit and Q 2 gives the proportion of variance in the data predicted by the model and indicates the accuracy of the prediction. The values of R 2 X = 0.345, R 2 Y = 0.881, Q 2 = 0.684 in the ESI+ mode and R 2 X = 0.279, R 2 Y = 0.881, and Q 2 = 0.58 in the ESI− mode demonstrated that the model possessed a satisfactory fit with good predictive power. Following this, permutation tests with 100 iterations were performed using the derived PLS-DA models to further evaluate the robustness of this method. The cross-validation plots of the permutation tests ( Figure 3B and D) indicated that the separation models were statistically sound and that their high predictability was not random or caused by overfitting, because all goodness-of-fit values (R 2 and Q 2 ) calculated from the permuted data (in green on the left) were lower than the corresponding original points on the right, and the Q 2 regression line (in blue) had a negative intercept. Discovery and identification of potential metabolic biomarkers: In order to select potential biomarkers among the thousands of variables, a combination of the FU, ET AL METLIN) . This process identified a total of 14 endogenous metabolites in the ESI+ mode and 14 in the ESI− mode as potential biomarkers (Table II) . Among them, nine metabolites were confirmed by reference standards and 19 were identified through online databases and analytical platforms (LC/Q-TOF/MS). The MS/MS spectra of these metabolites in our plasma sample showed a good match with those of the reference standards or online databases. Detailed information of these potential biomarkers is provided in Table II . In patients with CHD, the concentrations of 11 of these metabolites were significantly higher than in the controls, whereas the concentrations of the remaining 17 metabolites were significantly lower. These differences between the two groups are expressed as fold changes.
The relative standard deviations of these 28 biomarker intensities were calculated in the QC samples and were shown to vary from 9.22% to 24.75% (median: 17.89%). These data indicated that our metabolic profiling platform was robust and that alterations of the biomarkers arose from the disease state rather than from analytical errors. This robustness was also confirmed by the PCA scores plot comprising patients with CHD, control subjects, and QC samples.
The correlations between the top four principal components with concentrations of metabolites in Table II were also evaluated. As displayed in Table III , the associations between the top four principal components and metabolic markers have been seen from our analysis, which confirm the results shown in Table II .
Evaluation of the diagnosis potential of the metabolic biomarkers:
In order to analyze the diagnostic value of these markers, ROC curves were constructed for the 28 metabolites. However, there were no metabolites with AUC values greater than 0.8 (Table II) , suggesting the necessity of performing a diagnosis using multiple metabolite biomarkers.
A binary logistic regression model involving the 28 identified biomarkers was constructed in the training set. Figure 4A ). Using the best cut-off value of 0.5729, the sensitivity and specificity were 98.5% and 92.3%, respectively. For validation, we applied this FU, ET AL model to an independent cohort of 40 patients with CHD and 40 control subjects. The prediction model also exhibited a high AUC value of 0.929 (95% confidence interval: 0.874-0.984; Figure 4B ). At the same cut-off value of 0.57299, about 80% of patients with CHD and 92.5% of the control subjects in the test set were correctly classified. An external validation study confirmed the outstanding performance of the LC-MS plasma metabolomics plat- form for the diagnosis of patients with CHD. The relative concentrations of these nine plasma biomarkers across all groups are presented in Figure 5 . Compared with the control group, four metabolites (LysoPC (18 : 2), LysoPE (20 : 3), MG (20 : 0), and pentadecylic acid) showed increased concentrations in the patient group, whereas the other four metabolites (e.g., LysoPC (20 : 3) and myristic acid) showed decreased levels.
METABOLOMICS AS BIOMARKERS FOR CHD
Discussion
Altered metabolism is considered to be one of the hallmarks of CHD. In this regard, a better understanding of metabolic dysfunction in CHD is important. Me- tabolomics allows for the global assessment of thousands of small molecular endogenous metabolites in tissues or biological fluids, which is promising for the discovery of novel biomarkers and for increasing our understanding of the complex process of CHD development. A previous study has shown the diagnostic value of metabolomicsbased biomarkers in different types of coronary artery disease. 32) However, owing to the patient selection, that study exhibited a significant difference in the baseline characteristics between different groups, which affected the level of plasma metabolic biomarkers, resulting in statistical bias. In the present study, we enrolled subjects without significant differences in their baseline characteristics and used a new sample processing method, test conditions, and data analysis methods, which showed that untargeted plasma metabolomics could discriminate patients with CHD from controls. We also identified a panel of potential CHD biomarkers and proposed that the potential metabolic dysfunction is associated with CHD.
On the basis of this study, we found that the plasma concentrations of MG 18 : 0/0 : 0/0 : 0, MG 20 : 0, and MG 16 : 0 were upregulated in patients with CHD compared with the controls. Most circulating MGs are released by the action of lipoprotein lipase and hepatic lipase, which catalyze the hydrolysis of triglycerides to provide nonesterified fatty acids and MGs for tissue utilization. 33, 34) MGs and glycerol are further converted into free fatty acids using MG lipase. Within the intestinal wall, MGs are involved in the resynthesis of diglycerides and triglycerides through the monoacylglycerol pathway, followed by lymph transportation. 35) MGs are, therefore, central to the synthesis and breakdown of triglycerides, and a positive causal effect of plasma triglyceride levels on CHD risk has recently been shown in a large randomized FU, ET AL analysis. 36) Moreover, single-nucleotide polymorphisms of MG genes have been associated with CHD, even after adjustment for main cardiovascular risk factors. 34) Thus, it is possible that the perturbed MG metabolites identified in this study play pivotal pathogenic roles in the onset of CHD.
A notable metabolic feature of patients with CHD observed in this study was their remarkably disturbed phospholipid metabolism. As shown in Table II , a series of LysoPCs and LysoPEs were altered in patients with CHD compared with the controls. Lysophospholipids have essential structural and functional roles in the integrity and functionality of cell membranes. Abnormalities in lysophospholipid homeostasis alter the interactions of membrane-associated protein complexes that regulate cell signaling and myocardial metabolism. As shown in Figure  6 , several plasma LysoPCs and LysoPEs were generated from phosphatidylcholines and phosphatidylethanolamines by the activity of lecithin cholesterol acyltransferase. Low lecithin cholesterol acyltransferase activity has previously been linked to CHD, 9, 34, 37) although elevated levels of lysophospholipids have been reported to induce oxidative stress in endothelial cells, leading to AS and cardiovascular disease. 38, 39) Recently, it has been suggested in some population-based studies that lysophospholipids are inversely associated with CHD and its risk factors. 37, 40) Therefore, we inferred that the observed disturbed phospholipid metabolism is closely interrelated with CHD.
We also detected an increase in saturated fatty acids (SFAs) (e.g., stearic acid and palmitic acid) and a decrease in unsaturated fatty acids (UFAs) (e.g., myristoleic acid and palmitoleic acid) in patients with CHD compared with the controls. It was found in previous research that increased circulating SFAs can induce proinflammatory cytokines in human macrophages, contributing to the activation of atherosclerotic plaques. 41) Fatty acids are also an important energy source in the body, providing energy via β-oxidation. Under CHD conditions, the oxygen requirements of the heart exceed the oxygen supply. The downregulation of UFAs through enhanced fatty acid catalysis may supply the energy required during the initiation and progression of CHD.
Conclusions
In conclusion, this study provided proof of principle that LC-MS-based plasma metabolomics can accurately distinguish patients with CHD from controls. Our findings also identified a panel of characteristic metabolic markers associated with CHD. These altered metabolites were mainly related to the metabolism of MGs, phospholipids, and fatty acids. The elucidation of the associations between metabolic features and CHD events provided new information regarding biological mechanisms, which may provide clues for more effective treatment.
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